Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
Edwards Lifesciences (EW) Stock Price & Analysis
1,650 Followers
EW Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$60.57 - $96.12
Previous Close$85.09
Volume1.32M
Average Volume (3M)3.43M
Market Cap
$52.63B
Enterprise Value$50.40B
Total Cash (Recent Filing)$1.64B
Total Debt (Recent Filing)$694.90M
Price to Earnings (P/E)36.6
Beta1.16
Next Earnings
Jul 25, 2024EPS Estimate
$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.33
Shares Outstanding602,600,000
10 Day Avg. Volume2,984,288
30 Day Avg. Volume3,430,382
Standard Deviation0.09
R-Squared0.43
Alpha-0.00140
Financial Highlights & Ratios
Price to Book (P/B)10.32
Price to Sales (P/S)8.61
Price to Cash Flow (P/CF)116.10
P/FCF Ratio241.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.39
Enterprise Value/Gross Profit10.90
Enterprise Value/Ebitda28.35
Forecast
1Y Price Target
$95.89Price Target Upside9.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst recommends the stock based on solid first-quarter results and a strong performance outlook, with raised revenue and EPS projections.
Market Growth PotentialAnalyst's positive outlook on the stock is reinforced by the underpenetrated severe aortic stenosis market and strong TAVR volume growth projections from high-volume academic centers.
Product LaunchThe successful launch and premium pricing strategy of the Evoque TTVR system positions the company as a market leader in the transcatheter tricuspid valve replacement space.
Bears Say
Financial PerformanceAdjusted gross margin and operating margin were below the Street forecasts.
Market Share And CompetitionSurvey suggests modest deceleration of U.S. TAVR volumes in 2024 and 2025, with market share erosion expected for EW.
Revenue GrowthGlobal TAVR revenue growth came in under expectations.
---
Ownership Overview
1.06% Insiders
22.84% Mutual Funds
27.08% Other Institutional Investors
49.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $60.57 and its highest was $96.12 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 25, 2024 which is in 76 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 25, 2024. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.643 by $0.017.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is $0.69.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,600,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.66 in its last earnings report, beating expectations of $0.643. Following the earnings report the stock price went down -1.795%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 544M.
---
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$95.89 (9.80% Upside)
$95.89 (9.80% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.41%
12-Months-Change
Fundamentals
Return on Equity
21.59%
Trailing 12-Months
Asset Growth
12.54%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
EW Earnings Call
Q1 2024
0:00 / 0:00
---
EW Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$95.89
▲(9.80% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
23/32 ratings generated profit
1 Year Average Return
+19.09%
reiterated a buy rating 29 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 71.88% of your transactions generating a profit, with an average return of +19.09% per trade.
---